Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

What Are the Long-Term Side Effects of Imatinib for GIST?

At a Glance

Imatinib for GIST is typically taken for three to five years. Common long-term side effects include chronic fatigue, fluid retention like puffy eyes, stomach upset, anemia, and muscle cramps. Taking the pill with a large meal and avoiding grapefruit are essential for managing daily side effects.

In this answer

3 sections

01

How Long Will You Take Imatinib?

02

Managing Long-Term Side Effects

03

Adapting Your Treatment

For patients with a high-risk Gastrointestinal Stromal Tumor (GIST), targeted therapy with imatinib (Gleevec) is typically prescribed for at least three years after surgery to reduce the chance of the cancer returning. While imatinib is generally well-tolerated as a long-term treatment [1], it can cause chronic side effects that become a part of your daily routine. The most common long-term side effects include chronic fatigue, fluid retention, gastrointestinal distress, muscle cramps, anemia, and changes in kidney function, all of which require ongoing monitoring and management [2][3].

How Long Will You Take Imatinib?

The current standard of care for patients with high-risk GIST is to take adjuvant (post-surgery) imatinib for three years [4][5][6]. Your risk is determined by features like the tumor’s size, its location (such as the stomach versus the small intestine), the mitotic rate (how fast the cells are dividing), and whether the tumor ruptured before or during surgery [6][7]. Also, specific genetic mutations, like KIT exon 11 deletions, play a key role in how your care team will tailor your treatment [8][9].

In some cases, extending therapy beyond three years is a viable option and may further reduce the risk of relapse. This is particularly considered for patients with very high-risk features or tumors that did not originate in the stomach [10][11][4]. Ongoing clinical trials are also evaluating the benefits of 5 or more years of therapy, which is why your doctor might discuss a longer duration.

Managing Long-Term Side Effects

Taking a daily medication for years is a constant reminder of your cancer journey, which can be emotionally exhausting. It also means dealing with physical side effects that may be mild but persistent.

Gastrointestinal Distress and Daily Routine

Nausea, diarrhea, and general stomach upset are very common, especially when first starting the medication [2]. A crucial tip for your daily routine is to always take imatinib with a large, full meal and a large glass of water. Doing this helps protect your stomach lining and significantly minimizes nausea.

Diet and Drug Interactions

Imatinib is heavily processed in your body by an enzyme called CYP3A4 [12][13]. Because of this, it interacts strongly with certain foods and other medications. You should completely avoid grapefruit, Seville oranges, and starfruit, as they block this enzyme and can cause dangerously high levels of the drug to build up in your system [12]. Always review all new prescriptions, over-the-counter drugs, and herbal supplements with your pharmacist or oncologist to avoid accidental interactions.

Fluid Retention

A classic and frequent side effect of imatinib is fluid retention, particularly noticeable as swelling or puffiness around the eyes (periorbital edema) or in the lower legs and ankles [1][3]. While waking up with swollen eyes can be alarming, it is usually mild. Managing this often involves reducing your salt intake or, in more severe cases, your doctor may prescribe a mild diuretic (water pill) to help your body process the excess fluid.

Kidney Function Changes

Long-term imatinib therapy is associated with a steady, though partially reversible, decline in your eGFR (estimated glomerular filtration rate), a key marker of how well your kidneys are filtering waste [14][15][16]. Because of this, close and routine monitoring of your kidney function with blood tests is recommended, especially for older adults or those with pre-existing kidney issues or high blood pressure [17][18]. It is worth noting that imatinib can interfere with how creatinine (the waste product measured to calculate eGFR) is processed by the kidneys. This can sometimes make your kidney function look worse on paper than it actually is [19][20], which is why it is important to discuss lab results with your doctor rather than panicking over a single number.

Anemia and Chronic Fatigue

Routine blood tests are also important to monitor your red blood cell counts, as imatinib can cause persistent myelosuppression (a decrease in bone marrow activity), leading to chronic anemia [21]. Anemia is a significant contributor to chronic fatigue, a very common challenge for long-term GIST survivors. Managing this fatigue involves tracking your hemoglobin levels, pacing yourself, and sometimes adjusting the dose of your medication [22].

Muscle Cramps

Muscle cramps are another frequent and sometimes painful day-to-day reality of targeted therapy for GIST. Fortunately, interventions can help. For instance, L-carnitine has been shown to be a helpful supplement for relieving imatinib-associated muscle cramps and improving overall quality of life [23]. However, you should always speak with your care team before starting L-carnitine or any other over-the-counter supplement, as they can cause unexpected interactions.

Adapting Your Treatment

When side effects become difficult to tolerate, the clinical management of imatinib often involves a dose adjustment or reduction. This can successfully reduce symptoms while continuing to keep the tumor under control [22][3]. Additionally, some medical centers use therapeutic drug monitoring (TDM), which involves checking the level of imatinib in your blood to ensure it is within the right range to balance effectiveness and minimize toxicity [24][25][12].

Common questions in this guide

How long do I need to take imatinib for GIST?
The standard of care for high-risk GIST is to take imatinib for three years after surgery. However, depending on your tumor's features and specific genetic mutations, your oncologist may recommend extending treatment to five years or longer to reduce the risk of relapse.
How can I prevent stomach upset when taking imatinib?
Nausea and gastrointestinal distress are very common side effects. To minimize stomach upset, you should always take imatinib with a large, full meal and a large glass of water to help protect your stomach lining.
Why are my eyes puffy while taking imatinib?
Fluid retention is a classic side effect of imatinib, frequently causing mild swelling or puffiness around the eyes known as periorbital edema. Managing this often involves reducing your salt intake or taking a mild diuretic prescribed by your doctor.
What foods should I avoid while on imatinib?
You should completely avoid grapefruit, Seville oranges, and starfruit while taking imatinib. These foods block an enzyme that processes the medication, which can cause dangerously high levels of the drug to build up in your body.
Can imatinib cause muscle cramps?
Yes, muscle cramps are a frequent side effect of imatinib. Some patients find relief by taking L-carnitine supplements, but you should always discuss any new supplements with your care team first to avoid potential drug interactions.
How does imatinib affect my kidney function over time?
Long-term use of imatinib can cause a gradual decline in your kidney function over time. Your doctor will routinely monitor your kidney health using blood tests to track changes, especially if you have high blood pressure or pre-existing kidney issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the specific features of my original tumor, such as size and mitotic rate, would you recommend I continue imatinib beyond the standard three years?
  2. 2.How frequently should we monitor my eGFR and kidney function, and are there specific thresholds we should watch out for?
  3. 3.Am I a candidate for therapeutic drug monitoring to ensure my dose of imatinib is both effective and minimizing my side effects?
  4. 4.Should I be taking L-carnitine to manage my muscle cramps, and does it interact with any of my current medications?
  5. 5.If my fatigue or fluid retention becomes unmanageable, what is our threshold for discussing a dose reduction?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does GIST Treatment Cause Hair Loss? (Targeted Therapy)Do I Need to See a Sarcoma Specialist for GIST?What Happens When a GIST Tumor Ruptures? Risk & TreatmentIs GIST the Same as Stomach Cancer? Key DifferencesWhy Shrink a GIST Tumor Before Surgery with Imatinib?What Happens When Imatinib Stops Working for GIST?What is a High Mitotic Rate in GIST Pathology?What Is Wild-Type GIST and How Is It Treated?Where Does GIST Typically Spread or Recur?Why Is Small Intestine GIST Higher Risk Than Stomach GIST?

References

References (25)
  1. 1

    Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.

    Bauer S, Joensuu H

    Drugs 2015; (75(12)):1323-34 doi:10.1007/s40265-015-0440-8.

    PMID: 26187774
  2. 2

    Gastrointestinal Stromal Tumors.

    von Mehren M, Joensuu H

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(2)):136-143 doi:10.1200/JCO.2017.74.9705.

    PMID: 29220298
  3. 3

    A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

    Ben Ami E, Demetri GD

    Expert opinion on drug safety 2016; (15(4)):571-8 doi:10.1517/14740338.2016.1152258.

    PMID: 26865352
  4. 4

    Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor.

    Whooley P, Correa E, von Mehren M

    Expert review of anticancer therapy 2021; (21(5)):547-556 doi:10.1080/14737140.2021.1863149.

    PMID: 33353442
  5. 5

    Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

    Joensuu H, Eriksson M, Sundby Hall K, et al.

    JAMA oncology 2020; (6(8)):1241-1246 doi:10.1001/jamaoncol.2020.2091.

    PMID: 32469385
  6. 6

    Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.

    Bang YH, Ryu MH, Kim HD, et al.

    International journal of cancer 2022; (151(10)):1770-1777 doi:10.1002/ijc.34157.

    PMID: 35678337
  7. 7

    Why We Still Need the Better Risk Classification for GIST.

    Rutkowski P

    Annals of surgical oncology 2021; (28(5)):2425-2427 doi:10.1245/s10434-021-09620-9.

    PMID: 33625633
  8. 8

    Impact of preoperative tumor rupture timing on gastrointestinal stromal tumor prognosis: a retrospective multicentric cohort study.

    Chiguchi G, Cho H, Sato S, et al.

    Japanese journal of clinical oncology 2022; (52(3)):237-243 doi:10.1093/jjco/hyab200.

    PMID: 34933335
  9. 9

    Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.

    Wu X, Li J, Xu W, et al.

    Future oncology (London, England) 2018; (14(17)):1721-1729 doi:10.2217/fon-2017-0691.

    PMID: 29969914
  10. 10

    A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.

    Blay JY, Schiffler C, Bouché O, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2024; (35(12)):1157-1168 doi:10.1016/j.annonc.2024.08.2343.

    PMID: 39241959
  11. 11

    Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.

    Zhao R, Wang Y, Huang Y, et al.

    Scientific reports 2017; (7(1)):16834 doi:10.1038/s41598-017-17266-5.

    PMID: 29203825
  12. 12

    Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

    Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019; (25(3)):694-698 doi:10.1177/1078155217743565.

    PMID: 29199506
  13. 13

    Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?

    Buhl Rasmussen AS, Andersen CL, Weimann A, et al.

    Expert review of clinical pharmacology 2024; (17(3)):225-234 doi:10.1080/17512433.2024.2312256.

    PMID: 38345044
  14. 14

    Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.

    Sakurai M, Kikuchi T, Karigane D, et al.

    International journal of hematology 2019; (109(3)):292-298 doi:10.1007/s12185-019-02596-z.

    PMID: 30680668
  15. 15

    Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients.

    Singh AK, Hussain S, Ahmed R, et al.

    Nephrology (Carlton, Vic.) 2022; (27(4)):318-326 doi:10.1111/nep.14014.

    PMID: 34894374
  16. 16

    Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors.

    Lucijanic M, Krecak I

    International journal of hematology 2020; (112(2)):264 doi:10.1007/s12185-020-02915-9.

    PMID: 32519172
  17. 17

    Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.

    Sönmez Ö, Özgür Yurttaş N, İhtiyaroğlu İ, et al.

    Clinical lymphoma, myeloma & leukemia 2024; (24(4)):232-239 doi:10.1016/j.clml.2023.12.004.

    PMID: 38281820
  18. 18

    Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.

    Singh AK, Vidyadhari A, Bhurani D, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023; (29(8)):1928-1934 doi:10.1177/10781552231160113.

    PMID: 36862651
  19. 19

    Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

    Vidal-Petiot E, Rea D, Serrano F, et al.

    Clinical lymphoma, myeloma & leukemia 2016; (16(3)):169-74.

    PMID: 26795084
  20. 20

    Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia.

    Malkan UY, Haznedaroglu IC

    Open medicine (Warsaw, Poland) 2019; (14()):22-24 doi:10.1515/med-2019-0004.

    PMID: 30613793
  21. 21

    Severe persistent marrow aplasia in chronic myeloid leukemia (CML): An unusual complication of imatinib.

    Madabhavi I, Patel A, Anand A, Panchal H

    Journal of cancer research and therapeutics 2023; (19(2)):335-339 doi:10.4103/jcrt.JCRT_1594_20.

    PMID: 37006069
  22. 22

    A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.

    Jang BH, Kim BW, Lim KJ, et al.

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2015; (65(6)):366-9 doi:10.4166/kjg.2015.65.6.366.

    PMID: 26087692
  23. 23

    Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.

    Chae H, Ryu MH, Ma J, et al.

    Investigational new drugs 2020; (38(2)):493-499 doi:10.1007/s10637-019-00860-x.

    PMID: 31628586
  24. 24

    Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.

    Clarke WA, Chatelut E, Fotoohi AK, et al.

    European journal of cancer (Oxford, England : 1990) 2021; (157()):428-440 doi:10.1016/j.ejca.2021.08.033.

    PMID: 34597977
  25. 25

    The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.

    Van Obbergh F, Knoops L, Devos T, et al.

    Clinical biochemistry 2017; (50(7-8)):452-454 doi:10.1016/j.clinbiochem.2016.12.006.

    PMID: 28017570

This page provides educational information about the long-term use and side effects of imatinib for GIST. Always consult your oncologist before changing your dose, taking supplements, or altering your diet.

Get notified when new evidence is published on Gastrointestinal stromal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.